Completed PHASE1 INTERVENTIONAL NCT00004080

Gene Therapy in Treating Patients With Recurrent or Progressive Brain Tumors

Assessment of the Safety and Transduction Efficiency of SCH58500, An Adenoviral Vector p53 Delivery System, to Patients With Recurrent Malignant Brain Tumors

Sponsor: National Cancer Institute (NCI)

Conditions Brain and Central Nervous System Tumors

Interventions conventional surgery recombinant adenovirus-p53 SCH-58500

Updated 5 times since 2017 Last updated: Feb 6, 2009 Started: Dec 31, 1999

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Brain and Central Nervous System Tumors and is currently completed. National Cancer Institute (NCI) leads this study, which shows 5 recorded versions since 1999 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Dec 1999

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)

Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.